Consumer Insights
Uncover trends and behaviors shaping consumer choices today
Procurement Insights
Optimize your sourcing strategy with key market data
Industry Stats
Stay ahead with the latest trends and market analysis.
Colorectal Neoplasms represent one of the most prevalent malignancies worldwide, with approximately 1.9 million new cases diagnosed annually, creating a substantial global healthcare burden. Continuous progress in precision oncology, targeted therapies, and immunotherapy is reshaping the treatment landscape and expanding therapeutic possibilities. The colorectal neoplasms pipeline analysis by Expert Market Research highlights a robust clinical pipeline featuring innovative drug candidates designed to improve survival outcomes, address unmet medical needs, and advance personalized treatment strategies across various stages of disease progression.
Major companies involved in the colorectal neoplasms pipeline analysis include Merck Sharp & Dohme LLC, GE Healthcare and others.
Leading drugs currently in the pipeline include QL1706, and others.
The pipeline growth is driven by advances in targeted therapies and immunotherapies, expanding biomarker-guided treatment strategies, increasing clinical trial activity, and growing investment in precision oncology for colorectal neoplasms.
The Colorectal Neoplasms Pipeline Analysis Report by Expert Market Research gives comprehensive insights into colorectal neoplasms therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for colorectal neoplasms. The colorectal neoplasms report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The colorectal neoplasms pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with colorectal neoplasms treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to colorectal neoplasms.

Read more about this report - Request a Free Sample
The pipeline continues to advance through precision oncology and biomarker-driven therapeutic strategies. A significant milestone was achieved in February 2026, when the U.S. FDA granted traditional approval to encorafenib (Braftovi) in combination with cetuximab and fluorouracil-based chemotherapy for BRAF V600E-mutated metastatic colorectal cancer, based on the Phase III BREAKWATER trial. This approval highlights growing confidence in targeted combination therapies and is expected to accelerate pipeline innovation, encouraging the development of more personalized treatments for colorectal neoplasms.
Colorectal neoplasms remain a major global health burden, with approximately 1.9 million new colorectal cancer cases and more than 900,000 deaths reported worldwide in 2022, making it the third most common cancer and the second leading cause of cancer-related mortality. The disease predominantly affects adults aged 50 years and older, although incidence among younger adults continues to rise in several countries. Improved screening, earlier diagnosis, and advances in treatment are enhancing survival and long-term disease management.
This section of the report covers the analysis of colorectal neoplasms drug candidates based on several segmentations, including:
By Phase
The pipeline assessment report covers 50+ drug analyses based on phase:
By Drug Class
The colorectal neoplasms pipeline analysis report covers 50+ drug analyses based on drug classes:
By Route of Administration
The pipeline assessment report covers 50+ drug analyses based on the route of administration:
The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II covers a major share of the total colorectal neoplasms clinical trials. Early Phase I (2.24%), Phase I (32.24%), Phase II (50.09%), Phase III (13.88%), and Phase IV (1.55%), reflecting the distribution of drug candidates across the different stages of clinical development.
The drug molecule categories covered under the colorectal neoplasms pipeline analysis include small molecules, monoclonal antibodies, gene therapies. The colorectal neoplasms report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for colorectal neoplasms. In April 2025, the U.S. FDA approved nivolumab (Opdivo) plus ipilimumab (Yervoy) for adult and pediatric patients (12 years and older) with unresectable or metastatic MSI-H/dMMR colorectal cancer. The approval established the combination as a first-line immunotherapy option based on results from the CheckMate-8HW clinical trial.
The EMR report for the colorectal neoplasms pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed colorectal neoplasms therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in colorectal neoplasms clinical trials:
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for colorectal neoplasms. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of colorectal neoplasms drug candidates.
E7386 is a small molecule therapeutic developed by Eisai Co., Ltd. for the treatment of colorectal neoplasms. The candidate targets the Wnt/β-catenin signaling pathway, aiming to suppress tumor cell proliferation and improve treatment outcomes in patients with advanced colorectal cancer. The ongoing clinical study is expected to be completed in 2027. Eisai is a global pharmaceutical company recognized for its oncology portfolio and continued investment in innovative targeted therapies addressing unmet needs in gastrointestinal and solid tumors.
M9140 is an antibody-drug conjugate (ADC) developed by Merck KGaA, Darmstadt, Germany for colorectal neoplasms. The investigational therapy combines a monoclonal antibody targeting carcinoembryonic antigen (CEA) with a potent cytotoxic payload, selectively delivering treatment to CEA-expressing tumor cells while limiting systemic toxicity. The clinical program is expected to be completed in 2027. Merck KGaA maintains a robust oncology pipeline, focusing on precision medicines and next-generation targeted therapeutics for solid tumors worldwide.
LY4337713 is a small molecule investigational therapy being developed by Eli Lilly and Company for colorectal neoplasms. The candidate is designed to inhibit cancer-driving molecular pathways involved in tumor growth and survival, supporting precision treatment strategies for advanced colorectal malignancies. The ongoing clinical study is expected to be completed in 2028. Eli Lilly is a leading global biopharmaceutical company with an expanding oncology pipeline dedicated to developing innovative targeted therapies and improving outcomes for patients with difficult-to-treat cancers.
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
The Colorectal Neoplasms Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for colorectal neoplasms. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into colorectal neoplasms collaborations, regulatory environments, and potential growth opportunities.
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Scope of the Report |
Details |
|
Drug Pipeline by Clinical Trial Phase |
|
|
Route of Administration |
|
|
Drug Classes |
|
|
Leading Sponsors Covered |
|
|
Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Strategic Solutions for Informed Decision-Making
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.